Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
- PMID: 31403036
- PMCID: PMC6646625
- DOI: 10.1186/s40902-019-0210-8
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Abstract
Background: The aim of this study was to investigate clinical and pharmacoepidemiologic characteristics of medication-related osteonecrosis of the jaw.
Methods: The study population is comprised of 86patients who were diagnosed with ONJ at Ewha Womans University Mokdong Hospital from 2008 to 2015. Factors for epidemiologic evaluation were gender, age, location of lesion, and clinical history. The types of bisphosphonates, duration of intake, and the amount of accumulated dose were evaluated for therapeutic response. Clinical symptoms and radiographic images were utilized for the assessment of prognosis.
Results: Among the 86 patients, five were male, whereas 81 were female with mean age of 73.98 (range 45-97). Location of the lesion was in the mandible for 58 patients and maxilla in 25 patients. Three patients had both mandible and maxilla affected. This shows that the mandible is more prone to the formation of ONJ lesions compared to the maxilla. ONJ occurred in 38 cases after extraction, nine cases after implant surgery, six cases were denture use, and spontaneously in 33 cases. Seventy-six patients were taking other drugs aside from drugs indicated for osteoporosis. Most of these patients were diagnosed as osteoporosis, rheumatic arthritis, multiple myeloma, or had a history of cancer therapy. Higher weighted total accumulation doses were significantly associated with poorer prognosis (P < 0.05).
Conclusion: Dose, duration, route, and relative potency of bisphosphonates are significantly associated with treatment prognosis of osteonecrosis of the jaw.
Keywords: Bisphosphonate; MRONJ; Pharmacoepidemiology; Weight dose deposited.
Conflict of interest statement
Competing interestsThe authors declare that they have no competing interests.
Figures
Similar articles
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
-
[Clinical analysis of 24 cases of bisphosphonate-related osteonecrosis of the jaw].Zhonghua Kou Qiang Yi Xue Za Zhi. 2014 Sep;49(9):517-20. Zhonghua Kou Qiang Yi Xue Za Zhi. 2014. PMID: 25476210 Chinese.
-
Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.Oncologist. 2008 Aug;13(8):911-20. doi: 10.1634/theoncologist.2008-0091. Epub 2008 Aug 11. Oncologist. 2008. PMID: 18695259
-
[Bisphosphonate-associated osteonecrosis of the jaw].Mund Kiefer Gesichtschir. 2006 Mar;10(2):73-81. doi: 10.1007/s10006-005-0670-0. Mund Kiefer Gesichtschir. 2006. PMID: 16456688 Review. German.
-
Involvement of the maxillary sinus in bisphosphonate-related osteonecrosis of the jaw: Radiologic aspects.Am J Rhinol Allergy. 2017 Jan 1;31(1):36-39. doi: 10.2500/ajra.2017.31.4395. Am J Rhinol Allergy. 2017. PMID: 28234151 Review.
Cited by
-
In vitro effects of alendronate on fibroblasts of the human rotator cuff tendon.BMC Musculoskelet Disord. 2020 Jan 11;21(1):19. doi: 10.1186/s12891-019-3014-1. BMC Musculoskelet Disord. 2020. PMID: 31926548 Free PMC article.
-
Increased Level of Vascular Endothelial Growth Factors by 4-hexylresorcinol is Mediated by Transforming Growth Factor-β1 and Accelerates Capillary Regeneration in the Burns in Diabetic Animals.Int J Mol Sci. 2020 May 14;21(10):3473. doi: 10.3390/ijms21103473. Int J Mol Sci. 2020. PMID: 32423083 Free PMC article.
-
Immunomodulation for maxillofacial reconstructive surgery.Maxillofac Plast Reconstr Surg. 2020 Mar 5;42(1):5. doi: 10.1186/s40902-020-00249-4. eCollection 2020 Dec. Maxillofac Plast Reconstr Surg. 2020. PMID: 32206664 Free PMC article. Review.
-
Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.Front Endocrinol (Lausanne). 2021 Dec 9;12:774820. doi: 10.3389/fendo.2021.774820. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34956086 Free PMC article.
-
Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches.Antioxidants (Basel). 2021 Apr 27;10(5):680. doi: 10.3390/antiox10050680. Antioxidants (Basel). 2021. PMID: 33925361 Free PMC article. Review.
References
-
- Kulkarni R, Cymerman J, Pick A. Antiresorptive related osteonecrosis of the jaw bone (ARONJ); a single maxillofacial unit case series and analysis. Br J Oral Maxillofac Surg. 2014;52:74–82. doi: 10.1016/j.bjoms.2014.07.095. - DOI
LinkOut - more resources
Full Text Sources